AI R&D systems for regulated, messy-data environments.
Hugo Evers: R&D systems that turn ambiguous blockers into validated hypotheses and decision-grade systems, compounding progress across time, teams, and constraints.
Why it's different (in the agentic era).
Agents have changed what's possible. They haven't changed what matters: reliability, evaluation, and defensible outputs.
01
Reliability + code
Agents write code. Systems that stay correct, monitored, and defensible across edge cases, team changes, and regulatory scrutiny.
02
Bespoke modelling + optimisation
The mechanism or process gets modelled, then decisions are optimised under real-world constraints. Transferable methodology, not template stacking.
03
End-to-end loop ownership
Strategy, implementation, evaluation, and deployment in one path. One owner across the full loop prevents the handoff gaps where value disappears.
04
EU operating reality
Logging, traceability, human oversight, robustness, and security-aware patterns built in, not retrofitted after a compliance conversation.
EU high-risk AI requirements emphasise logging/traceability, human oversight, robustness and cybersecurity. digital-strategy.ec.europa.eu ↗
Selected work.
A few representative projects. Clients anonymised where needed; outcomes kept honest.
Marketplace optimisation
Bespoke modelling + optimisation under constraints
- +32% performance at fixed budget
- Shipped with evaluation + deployment path
- Bespoke bidding model, not off-the-shelf ML
Clinical decision support
Privacy-preserving, explainable decision support
- Structured for regulatory defensibility
- Workflow integration: fits clinical reality
- Explainability built in from day one
Real-world outcomes modelling
Patient insight with interpretability + uncertainty
- Mechanistic model, not black-box ML
- Uncertainty quantification for clinical teams
- Designed for senior decision-making audiences
Platform work, biotech scale-up
R&D data platform enabling large-scale annotation, sharing, and traceability across multi-site teams.
How it works.
Operating principles: so you know what to expect before the first call.
What you can expect
- Fast framing of the decision interface before any build
- Tested hypotheses over personal opinions
- Evaluation discipline: baselines, failure modes, benchmarks
- Delivery artifacts you can reuse: plans, harnesses, diagrams
- Clear weekly cadence with written updates
What gets avoided
- Endless POCs with no ownership or path to production
- Tool-first decisions that lock in before problem is understood
- Black-box outputs without validation or audit trail
- Overpromising on timelines, data quality, or capability
Sounds like a fit?
30-min triage. No pitch. You leave with a structured answer to your blocker.
Three pillars, one outcome: compounding R&D velocity.
Strategy without engineering is a deck. Engineering without modelling is a pipeline to nowhere. All three closing the loop is what makes R&D systems compound.
Strategy
Value-driven discovery
- Decision interface definition
- Hypothesis shortlist
- Risk + constraint mapping
- Sprint / roadmap plan
Engineering
Reliable systems + throughput
- Eval harness + baselines
- Deployment-ready pipeline
- Monitoring + alerting
- Reproducible artifacts
Modelling
Mechanism + optimisation
- Bespoke model design
- Constraint-aware optimisation
- Uncertainty quantification
- Interpretability layer
Why not just…
Honest comparison. Each option has real strengths: this is where each one breaks for regulated, messy-data R&D work.
| Option | Pros | Where it breaks down |
|---|---|---|
| Internal team + agents | Speed for isolated, well-scoped tasks |
|
| Big consultancy | Capacity and brand reassurance |
|
| Generalist freelancer | Lower cost, flexible scope |
|
| Biolytics You |
| |
Book triage
Book the 30-min triage,
you leave with a plan.
No pitch, no deck. A structured conversation about your specific blocker. See if the sprint: or something else: is the right move.